Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

HungaryBack to Hungary

Clinical trials in Szolnok – page 9

123 clinical trials in Szolnok, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.

Szolnok at a glance
123
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

123 trials in Szolnok

Open in trial search

Small cell lung cancer extensive stage

Not recruiting

Study of Lurbinectedin and Atezolizumab for Maintenance Therapy in Patients with Extensive-Stage Small-Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Breast cancer metastatic

Not recruiting

Study of inavolisib, palbociclib and fulvestrant in patients with PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:F. Hoffmann-La Roche AG

Small cell lung cancer

Not recruiting

Study of Lurbinectedin Alone or with Irinotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Irinotecan
  • Sponsor:Pharma Mar S.A.

Non-small cell lung cancer stage III

Not recruiting

Study of Atezolizumab and Tiragolumab Compared to Durvalumab for Patients with Advanced Non-Small Cell Lung Cancer After Chemoradiation

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:F. Hoffmann-La Roche AG

Dermatitis atopic

Not recruiting

Study of Upadacitinib and Topical Corticosteroids for Adolescents and Adults with Moderate to Severe Eczema

Registered drug
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hydrocortisone
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Rheumatoid arthritis

Not recruiting

Study Comparing Upadacitinib and Adalimumab for Adults with Moderate to Severe Rheumatoid Arthritis Not Responding to a Single TNF Inhibitor

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Non-small cell lung cancer stage IV

Not recruiting

Study Comparing MK-7684A and Pembrolizumab for Patients with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Bladder transitional cell carcinoma+2

Not recruiting

Study of Enfortumab Vedotin and Pembrolizumab for Patients with Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Seagen Inc.

Psoriasis

Not recruiting

Study on the Effectiveness and Safety of JNJ-77242113 for Treating Plaque Psoriasis in Special Areas for Patients with Moderate to Severe Symptoms

Investigational
Countries:HungaryHungary
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:JNJ-77242113
  • Sponsor:Janssen Cilag International

Bladder cancer

Not recruiting

Study Comparing Enfortumab Vedotin and Pembrolizumab with Chemotherapy for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Non-small cell lung cancer

Not recruiting

Study of Pembrolizumab with Drug Combination for Patients with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Boserolimab
  • Sponsor:Merck Sharp & Dohme LLC

Bladder cancer+2

Not recruiting

Study of Pembrolizumab, Cisplatin, and Gemcitabine for Patients with Muscle-Invasive Bladder Cancer Eligible for Cisplatin Treatment

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Merck Sharp & Dohme LLC

Other cities in Hungary

The busiest research cities in the country

All 71 cities in Hungary

Clinical research in Szolnok

What the registry says about research in the country

01 Dermatology Research

Extensive clinical trials focusing on plaque psoriasis and atopic dermatitis treatments, evaluating novel therapies for moderate to severe cases.

  • Plaque Psoriasis Studies
  • Genital Psoriasis Research
  • Atopic Dermatitis Treatments

Multiple trials testing new biological treatments and long-term safety assessments for chronic skin conditions.

02 Oncology Studies

Comprehensive research into various cancer types, with particular focus on lung cancer treatments and innovative immunotherapy approaches.

  • Non-Small Cell Lung Cancer
  • Small Cell Lung Cancer
  • Urothelial Cancer
  • Head and Neck Cancer

Investigation of novel combination therapies and targeted treatments for advanced stage cancers.

03 Cardiovascular and Metabolic Research

Studies examining treatments for heart failure prevention and management of cardiovascular conditions.

  • Heart Failure Prevention
  • Chronic Kidney Disease
  • Atherosclerotic Cardiovascular Disease

Innovative approaches to reducing cardiovascular risks and improving patient outcomes.

Back to HungaryAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.